| Name | Title | Contact Details |
|---|---|---|
Sumita Ray |
General Counsel | Profile |
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
Arcxis Biotechnologies Inc is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. The Company`s technology will broaden the end user experience through improved data quality and simplified workflows to benefit discoveries and diagnosis in healthcare.
Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Delinia has assembled a leadership team, Board of Directors and Scientific Advisory Board comprised of experienced investors, world-class academicians and industry veterans with proven track records for building exceptional life sciences companies.